Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis
Provided By GlobeNewswire
Last update: Jun 4, 2025
Denifanstat met all primary and secondary endpoints versus placebo
Denifanstat was well tolerated
Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne
Read more at globenewswire.com8.72
+1.68 (+23.86%)
Find more stocks in the Stock Screener
SGMT Latest News and Analysis
8 days ago - ChartmillHere are the top movers in Thursday's session.Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
17 days ago - ChartmillThese stocks are moving in today's pre-market sessionAs we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
